Royalty Pharma (RPRX)
Royalty Pharma Statistics
Share Statistics
Royalty Pharma has 433.32M shares outstanding. The number of shares has increased by -4.15% in one year.
| Shares Outstanding | 433.32M |
| Shares Change (YoY) | -4.15% |
| Shares Change (QoQ) | -2.47% |
| Owned by Institutions (%) | 71.44% |
| Shares Floating | 334.29M |
| Failed to Deliver (FTD) Shares | 522 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 13.75M, so 3.17% of the outstanding shares have been sold short.
| Short Interest | 13.75M |
| Short % of Shares Out | 3.17% |
| Short % of Float | 4.11% |
| Short Ratio (days to cover) | 2.46 |
Valuation Ratios
The PE ratio is 13.29 and the forward PE ratio is 6.17. Royalty Pharma's PEG ratio is -0.3.
| PE Ratio | 13.29 |
| Forward PE | 6.17 |
| PS Ratio | 5.04 |
| Forward PS | 3.1 |
| PB Ratio | 1.1 |
| P/FCF Ratio | 4.12 |
| PEG Ratio | -0.3 |
Enterprise Valuation
Royalty Pharma has an Enterprise Value (EV) of 18.1B.
| EV / Sales | 8 |
| EV / EBITDA | 14.01 |
| EV / EBIT | 6.54 |
| EV / FCF | 6.54 |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.44 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 5.89 |
| Debt / FCF | 2.75 |
| Interest Coverage | 5.72 |
Financial Efficiency
Return on Equity is 8.31% and Return on Invested Capital is 4.64%.
| Return on Equity | 8.31% |
| Return on Assets | 4.71% |
| Return on Invested Capital | 4.64% |
| Revenue Per Employee | $30.19M |
| Profits Per Employee | $11.45M |
| Employee Count | 75 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 472M |
| Effective Tax Rate | 35.46% |
Stock Price Statistics
The stock price has increased by 17.92% in the last 52 weeks. The beta is 0.49, so Royalty Pharma's price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | 17.92% |
| 50-Day Moving Average | 32.49 |
| 200-Day Moving Average | 28.7 |
| Relative Strength Index (RSI) | 52.26 |
| Average Volume (20 Days) | 4.76M |
Income Statement
In the last 12 months, Royalty Pharma had revenue of 2.26B and earned 859M in profits. Earnings per share was 1.92.
| Revenue | 2.26B |
| Gross Profit | 2.26B |
| Operating Income | 1.29B |
| Net Income | 859M |
| EBITDA | 1.29B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | 1.92 |
Balance Sheet
The company has 929.03M in cash and 7.61B in debt, giving a net cash position of -6.68B.
| Cash & Cash Equivalents | 929.03M |
| Total Debt | 7.61B |
| Net Cash | -6.68B |
| Retained Earnings | 2.85B |
| Total Assets | 18.22B |
| Working Capital | 548.52M |
Cash Flow
In the last 12 months, operating cash flow was 2.77B and capital expenditures 0, giving a free cash flow of 2.77B.
| Operating Cash Flow | 2.77B |
| Capital Expenditures | 0 |
| Free Cash Flow | 2.77B |
| FCF Per Share | 6.19 |
Margins
Gross margin is 100%, with operating and profit margins of 57.07% and 37.94%.
| Gross Margin | 100% |
| Operating Margin | 57.07% |
| Pretax Margin | 58.79% |
| Profit Margin | 37.94% |
| EBITDA Margin | 57.07% |
| EBIT Margin | 57.07% |
| FCF Margin | 122.31% |
Dividends & Yields
RPRX pays an annual dividend of $0.85, which amounts to a dividend yield of 2.54%.
| Dividend Per Share | $0.85 |
| Dividend Yield | 2.54% |
| Dividend Growth (YoY) | 4.76% |
| Payout Ratio | 44.5% |
| Earnings Yield | 7.52% |
| FCF Yield | 24.25% |
Analyst Forecast
The average price target for RPRX is $45.5, which is 40.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $45.5 |
| Price Target Difference | 40.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 1.3 |
| Piotroski F-Score | 5 |